Investors – Koite Health

Why Invest in Koite Health

Koite Health is an investment with significant international growth potential.
Our goal is to strongly increase our shareholder value, while offering new treatment solutions for medical professionals and high-quality products to our consumer customers.

• Koite Dual-light technology® is a unique health innovation; there is nothing like it on the market

• Scientifically proven and patent-protected

• Excellent product pipeline

• Significant growth potential in the €20 billion total available market segment in dental care, Lumoral® is suitable for both preventive and treatment use.

• Growing recurring revenue from Lumorinse tablet sales. The new Lumoral subscription model improves adherence and lowers purchase threshold. The new Lumoral® 2.0 with the mobile app will further strengthen this.

• Extremely high 88% recommendation rate among dental professionals

• Strong development program to enter the $1.2B mucositis treatment market

• Excellent partnering and licensing opportunities

• High customer loyalty, more than 81% of monthly subscribers to Lumorinse® tablets have continued their subscription after 12 months.

• Experienced management team with expertise in world-class technical innovations, scaling up international medical technology companies and leading product design & clinical testing of medical innovations.

Applications and pipeline

Koite’s patented technologies offer diverse opportunities across multiple business sectors:

Lumoral.

Lumoral® and Lumorinse® products Problem: 95% of oral diseases are caused by bacteria

Target: Supragingival plaque

Approach: continuous weekly/daily use

Advantages: Scalable, patient-driven, cost-effective

Competition: No direct competition, Chlorhexidine and other mouthwashes can be considered indirect competition

Oncolum.

Problem: Oral mucositis is a cancer treatment side-effect

Target: Mucous membranes to reduce pain, improve cellular health & healing

Approach: PBM with red and NIR

light, weekly/daily use

Advantages: Scalable, patient-driven, cost-effective

Competition: Many in-office photobiomodulatory devices, ATP38, Thorlabs

Wound healing.

Problem: Antimicrobial resistance

Target: difficult-to-treat wounds

Approach: in hospital use

Advantages: Key USA patents approved*. Strong in vitro data to demonstrate effectiveness against MRSA infections

Competition: No direct competition in the market. Multiple aPDT solutions in development

Lumoral is an effective and sustainable solution for bacteria-caused dental illnesses

Koite Health was founded to respond to the growing need for new treatment solutions against bacteria-based dental illnesses. In the EU, 51% of adults suffer from various bacteria-based oral diseases and worldwide they impact more than one billion people.

We launched Lumoral in 2020 as the first antibacterial photodynamic treatment for home use. Three years later, Lumoral has more than 40,000 users and has performed over 2 million antibacterial treatments.

Lumoral has been launched in Germany, Italy, Denmark, Great Britain, and there are several other new international markets on the way, including France, Poland, Portugal and the USA.

We are now raising growth capital to support the international rollout of Lumoral and to support the continuing research and clinical studies for new treatment areas with the Lumoral technology

Oncolum is an innovative device for the prevention and treatment of oral mucositis.

Oncolum is being developed to address a significant unmet medical need in cancer care. Oral mucositis is a painful and debilitating side effect of many cancer treatments—affecting up to 40% of chemotherapy patients and as many as 70% of those receiving head and neck cancer therapies. The condition causes severe pain, difficulties in speaking and swallowing, and often leads to interruptions in cancer treatment.

Oncolum is a revolutionary photobiomodulation device designed for the prevention and treatment of oral mucositis. Building on Koite Health’s proven Lumoral technology, Oncolum applies clinically validated light-based therapy in a medical-grade format tailored for oncology patients.

Koite Health is now preparing for clinical studies and strategic partnerships to advance Oncolum toward regulatory approval and clinical adoption.

The Market

Dental Diseases

80% of adults have gingivitis
50% of adults over 30 have periodontal disease
20 million dental implants placed annually, with 20% facing infection complications
1 billion people suffer from severe gum disease (periodontitis)

Lumoral Opportunity

€8.4 b market in prevention and treatment of periodontal and peri-implant diseases

~€10 b market in oral hygiene improvement (electric toothbrush and mouthwash segment)

No major innovations in oral hygiene or plaque control in the past 50 years

Oncolum Opportunity – USA Market

Total Addressable Market: $784 M (784,000 oral mucositis patients @ $1,000 per patient)

Serviceable Available Market: $392 M (50% of OM patients ≈ 392,000 patients per year)

Serviceable Obtainable Market: $39 M (10% market penetration @ $1,000 per patient)

Business model

Koite Health focuses on product development, clinical trials with academic partners and the production of clinical proof for new treatment areas for the Lumoral method – as well as the distribution at the home markets.

The home markets

Koite Health handles the marketing and distribution of Lumoral products in our home markets – Finland and Sweden. Products are marketed and promoted through dental professionals and directly to consumers.

Local distribution partners

Outside Finland and Sweden, Lumoral is marketed and distributed by local partners with established networks in oral care. These carefully selected partners sign exclusive agreements for their respective markets and are responsible for all launch and promotional activities.

New markets start with professional marketing

In each new market, Lumoral is first introduced through dental professionals, the scientific community, and key opinion leaders. Consumer marketing and broader campaigns follow once professional awareness is established.

Initial sales and recurring revenues

Koite Health generates revenue from sales of Lumoral Starter Kits and recurring revenues from Lumorinse tablets, which are an essential part of the treatment.

The Global Economic Impact of Dental Diseases

Total Cost of Bacteria-Related Dental Diseases

Direct Cost of Dental Diseases

Indirect Cost of Dental Diseases

Direct Costs of Periodontal Disease

Indirect Costs of Periodontal Disease

If you are a shareholder or interested in investing in Koite Health, please leave a note or contact Investor Relations at ir@koitehealth.com